the Question Should we, as society, offer pharmaceuticals and therapy sponsors (including academic developers) unique incentives to develop and clinically test combination therapies, prior to trying to get each component approved separately and then testing combinations? ISSUE With many pharmaceutical executives and managers believing the development of combination therapies—most particularly, drug cocktails—is “financial suicide,” the question [...]